Vmn2r108 Inhibitors
Vmn2r108 inhibitors are a class of chemical compounds that interact with the Vmn2r108 receptor, which is a member of the vomeronasal type-2 receptor (V2R) family. V2Rs are a group of G-protein-coupled receptors (GPCRs) that are predominantly found in the vomeronasal organ (VNO) of certain animals, including rodents. The VNO is a chemosensory organ that is involved in the detection of pheromones, chemical signals that play a crucial role in social and reproductive behaviors. Vmn2r108 receptors are encoded by a specific gene that belongs to a larger gene family which is diverse and has many variants, each responding to different molecules. The inhibitors of Vmn2r108 specifically prevent the normal binding and activation of these receptors, which can be studied to understand the biological processes controlled by Vmn2r108 signaling.
The chemical structure of Vmn2r108 inhibitors can vary widely, as they are designed to fit into the binding site of the Vmn2r108 receptor, effectively blocking the receptor's natural ligands from attaching and initiating a cellular response. The inhibitors usually mimic the shape and charge distribution of the natural ligands, but with enough differences to prevent activation of the receptor. The interactions between Vmn2r108 inhibitors and their target receptor are often characterized by a combination of hydrogen bonding, hydrophobic forces, and van der Waals interactions, which are all critical in establishing the specificity and strength of the inhibitory action. The study of these inhibitors can provide valuable insights into the structural aspects of ligand-receptor interaction and the molecular mechanisms underlying signal transduction in the VNO. Through these studies, researchers can gain a better understanding of how chemical signaling shapes the behavior of animals, especially those related to pheromone detection.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR inhibitor that can downregulate the EGFR signaling pathway. Vmn2r108, if it is part of this pathway, can have its activity diminished due to reduced downstream signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is a key regulator of cell growth and proliferation. Inhibition of mTOR can lead to a decrease in cellular activities that require mTOR signaling, potentially affecting Vmn2r108 if it is implicated in these cellular processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which can suppress the MAPK pathway involved in inflammatory responses and other cellular processes. If Vmn2r108 is involved in pathways downstream of p38 MAPK, its activity could be indirectly inhibited. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can reduce AKT phosphorylation and subsequent signaling. As PI3K/AKT pathway is crucial for multiple cellular functions, inhibiting this pathway could affect Vmn2r108 activity if it is linked to this pathway. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor, which can lead to alterations in cytoskeletal dynamics and cell motility. If Vmn2r108 function is related to these cellular processes, inhibition of ROCK could lead to decreased Vmn2r108 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an MEK inhibitor, which impedes the ERK/MAPK signaling pathway. ERK/MAPK is involved in cell cycle regulation and differentiation, so inhibiting this pathway may affect Vmn2r108 if it plays a role in these processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor similar to PD98059, and it can also impede the ERK/MAPK signaling pathway, potentially leading to reduced Vmn2r108 activity if it is implicated in this pathway. | ||||||
WZ 4002 | 1213269-23-8 | sc-364655 sc-364655A | 10 mg 50 mg | $180.00 $744.00 | 1 | |
WZ4002 is a selective inhibitor of mutant forms of EGFR, which can decrease signaling through the EGFR pathway. This may indirectly inhibit Vmn2r108 if it relies on EGFR pathway signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, potentially reducing the activity of transcription factors regulated by JNK. If Vmn2r108 is influenced by JNK signaling, its activity could be indirectly diminished. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 inhibits NF-κB activation, which plays a role in immune and inflammatory responses. Vmn2r108 activity may be indirectly inhibited if it is involved in NF-κB related pathways. | ||||||